Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

2,689

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

March 31, 2011

Conditions
Essential Hypertension
Interventions
DRUG

olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo

One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.

DRUG

Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo

One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.

DRUG

olmesartan medoxomil + amlodipine + hydroclororthiazide

One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.

DRUG

olmesartan medoxomil + amlodipine + hydroclororthiazide

One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.

DRUG

olmesartan medoxomil + amlodipine + hydroclororthiazide

One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.

DRUG

olmesartan medoxomil + amlodipine

One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day

DRUG

olmesartan medoxomil + amlodipine

One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day.

DRUG

olmesartan medoxomil + amlodipine

One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day.

Trial Locations (133)

Unknown

Antwerp

Buizingen

De Pinte

Drongen

Ghent

Gilly

Merksem

Mouscron

Tremelo

Wichelen

Burgas

Pleven

Plovdiv

Sofia

Stara Zagora

Veliko Tarnovo

Benátky nad Jizerou

Brodce

Havířov

Jičín

Mladá Boleslav

Moravská Ostrava

Pilsen

Prachatice

Prague

Sokolov

Copenhagen

Frederiksberg

Roskilde

Berlin

Cloppenburg

Delitzsch

Dresden

Erfurt

Essen

Hamburg

Heidelberg

Leipzig

Northeim

Simmern

Wallerfing

Wiesbaden

Budapest

Debrecen

Hódmezővásárhely

Jászberény

Kaposvár

Kecskemét

Orosháza

Pécs

Székesfehérvár

Veszprém

Zalaegerszeg

Bologna

Brescia

Chieti

Ferrara

Foggia

Genova

Palermo

Parma

Perugia

Pisa

Roma

Sassari

Stradella Pavia

Cēsis

Daugavpils

Jēkabpils

Ogre

Riga

Tukums

Varakļāni

Ventspils

Deurne

Eindhoven

Lichtenvoorde

Lieshout

Rotterdam

Utrecht

Bialystok

Dębica

Gdansk

Gdynia

Jastrzebia Zdroj

Krakow

Lublin

Mielec

Opole

Szczecin

Warsaw

Wroclaw

Arad

Bucharest

Craiova

Iași

Piteşti

Ploieşti

Sibiu

Suceava

Timișoara

Barnaul

Moscow

Novosibirsk

Saint Petersburg

Tyumen

Yaroslavl

Banska Bysterica

Bratilslava

Nitra

Považská Bystrica

Rimavská Sobota

Žilina

Badalona

Barcelona

Ferrol

Lleida

Madrid

Petrel

Salamanca

Santiago de Compostela

Valencia

Dnipropetrovsk

Donetsk

Kharkiv

Kyiv

Lutsk

Lviv

Odesa

Simferopol

Vinnytsia

Zaporizhzhya

Zhytomyr

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT00923091 - Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension | Biotech Hunter | Biotech Hunter